KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Intangibles (2019 - 2026)

Pacira BioSciences has reported Intangibles over the past 14 years, most recently at $353.2 million for Q1 2026.

  • For Q1 2026, Intangibles fell 18.79% year-over-year to $353.2 million; the TTM value through Mar 2026 reached $353.2 million, down 18.79%, while the annual FY2025 figure was $368.1 million, 13.59% down from the prior year.
  • Intangibles for Q1 2026 was $353.2 million at Pacira BioSciences, down from $368.1 million in the prior quarter.
  • Over five years, Intangibles peaked at $609.6 million in Q1 2022 and troughed at $353.2 million in Q1 2026.
  • A 5-year average of $476.3 million and a median of $468.9 million in 2024 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: skyrocketed 544.76% in 2022 and later dropped 18.79% in 2026.
  • Year by year, Intangibles stood at $540.5 million in 2022, then decreased by 10.6% to $483.3 million in 2023, then dropped by 11.85% to $426.0 million in 2024, then fell by 13.59% to $368.1 million in 2025, then dropped by 4.04% to $353.2 million in 2026.
  • Business Quant data shows Intangibles for PCRX at $353.2 million in Q1 2026, $368.1 million in Q4 2025, and $382.4 million in Q3 2025.